Bio-defense partnerships Leverage VxP’s US Bio-Defense Grid experience and FDA-audited facilities to position as a trusted CDMO partner for government and public health contracts, including live virus vaccine and biologics development.

Small and biologics expertise Offer end-to-end development and manufacturing capabilities for both small molecules and biologics, including mammalian and microbial systems, which broadens target opportunities across pharma and biotech clients seeking integrated solutions.

Global yet nimble Highlight multi-region footprint (US, Europe, India, East Asia) with a track record of collaborations to attract mid-market and virtual companies seeking scalable manufacturing and regulatory support without large enterprise commitments.

Regulatory readiness Emphasize regulatory support and FDA-aligned quality, aiding prospects that require efficient navigation from preclinical to clinic or market, potentially shortening time-to-market for complex biologics and vaccines.

Cost and speed value Position as a cost-effective, accelerated development partner capable of handling preclinical/toxicology in multiple animal models and analytical support, appealing to startups and virtual companies aiming to de-risk timelines and budgets.